Literature DB >> 17118099

N-terminal pro-brain natriuretic peptide for detection of cardiovascular stress in patients with obstructive sleep apnea syndrome.

Edmond Vartany1, Michael Imevbore, Mary O'Malley, Christopher Manfredi, Carol Pasquarella, Leonard Scinto, Jonathan Fine.   

Abstract

Patients with obstructive sleep apnea syndrome (OSAS) have an elevated incidence of cardiovascular events that may be related to an increased ventricular load and hypoxemia caused by apneas and hypopneas. N-terminal pro-brain natriuretic peptide (NTproBNP) appears to be an excellent marker of myocardial stretch and could serve as an indicator of subclinical cardiac stress, thereby identifying a patient population at risk for cardiac effects from OSAS. Adult patients presenting with suspected OSAS and scheduled for nocturnal polysomnography were recruited. Patients with heart or renal failure or severe lung disease were excluded. NTproBNP was measured the evening before and the morning after sleep. Blood pressure (BP) was monitored intermittently throughout the night. Fifteen male and 15 female subjects with a mean +/- SD body mass index of 38.2 +/- 9.8 were studied. Mean Apnea-Hypopnea Index (AHI) was 38.4 +/- 26, with 17 subjects having severe OSAS (AHI > 30). No subject had a significant rise in BP. NTproBNP values overnight decreased in 19 patients and rose in 11 (mean change 3.8 +/- 33 pg mL(-1)), but only one patient had an abnormal morning value. Three patients had an abnormal NTproBNP value prior to sleep, but their levels decreased with sleep. No correlations were detected between the evening baseline or postsleep NTproBNP levels and OSAS. Monitoring pre- and postsleep NTproBNP levels revealed no association with the occurrence or degree of OSAS, making it unlikely that NTproBNP could serve as a marker of cardiac stress in OSAS patients with stable BP and without overt heart failure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17118099     DOI: 10.1111/j.1365-2869.2006.00551.x

Source DB:  PubMed          Journal:  J Sleep Res        ISSN: 0962-1105            Impact factor:   3.981


  7 in total

1.  N-terminal pro-B-type naturetic peptide (NTBNP): so much promise and such a disappointment.

Authors:  Neil S Cherniack
Journal:  Sleep Breath       Date:  2008-03       Impact factor: 2.816

Review 2.  Sleep apnea in total joint arthroplasty patients and the role for cardiac biomarkers for risk stratification: an exploration of feasibility.

Authors:  M Melanie Lyons; Nitin Y Bhatt; Elizabeth Kneeland-Szanto; Brendan T Keenan; Joanne Pechar; Branden Stearns; Nabil M Elkassabany; Stavros G Memtsoudis; Allan I Pack; Indira Gurubhagavatula
Journal:  Biomark Med       Date:  2016       Impact factor: 2.851

Review 3.  What can blood biomarkers tell us about cardiovascular risk in obstructive sleep apnea?

Authors:  Ivan Guerra de Araújo Freitas; Pedro Felipe Carvalhedo de Bruin; Lia Bittencourt; Veralice Meireles Sales de Bruin; Sérgio Tufik
Journal:  Sleep Breath       Date:  2015-02-26       Impact factor: 2.816

4.  N-terminal pro-B-type natriuretic peptide and functional capacity in patients with obstructive sleep apnea.

Authors:  Micha T Maeder; Peter Ammann; Hans Rickli; Otto D Schoch; Wolfgang Korte; Christoph Hürny; Jonathan Myers; Thomas Münzer
Journal:  Sleep Breath       Date:  2008-03       Impact factor: 2.816

Review 5.  Clinical applications of N-terminal pro B-type natriuretic peptide in heart failure and other cardiovascular diseases.

Authors:  Da-Rong Pu; Jun R Chiong; Qi-chang Zhou
Journal:  Heart Fail Rev       Date:  2010-07       Impact factor: 4.214

6.  Association between obstructive sleep apnea and elevated levels of type B natriuretic peptide in a community-based sample of women.

Authors:  Mirjam Ljunggren; Bertil Lindahl; Jenny Theorell-Haglöw; Eva Lindberg
Journal:  Sleep       Date:  2012-11-01       Impact factor: 5.849

Review 7.  A clinical approach to obstructive sleep apnea as a risk factor for cardiovascular disease.

Authors:  Micha T Maeder; Otto D Schoch; Hans Rickli
Journal:  Vasc Health Risk Manag       Date:  2016-03-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.